FDA Grants Approval to Atezolizumab for Alveolar Soft Part Sarcoma
On December 9, 2022, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS). Efficacy was evaluated in Study ML39345 (NCT03141684), an open-label, single-arm study in 49 adult and pediatric patients with unresectable or […]
Summer 2022: Updated Clinical Research on Alveolar Soft Part Sarcoma
Below are links to eighteen publications describing clinical studies of ASPS with novel treatments as well as preclinical information on ASPS. The ASPS community is thankful to all the Principle Investigators, Oncologists and Researchers who are working with us to find a cure for ASPS! Anlotinib with Toripalimab for ASPS Therapy Complete Response of Metastatic […]
2019 Progress Report on Alveolar Soft Part Sarcoma – American Society of Clinical Oncology (ASCO) annual meeting
We selected to highlight 3 studies that were presented this year at the ASCO conference: 1. Treatment of ASPS with anlotinib (a new oral tyrosine kinase inhibitor therapy), Clinical trial information: NCT02449343 2. Combination treatment of ASPS with NKTR214 (immune modulator) and nivolumab (immune checkpoint inhibitor), Clinical trial information: NCT03282344 3. Successful generation of patient-derived xenografts and cell […]
NIH study finds Cediranib benefits patients with ASPS
An experimental drug, cediranib, may benefit alveolar soft part sarcoma (ASPS) patients, according a recent clinical trial. The trial, carried out by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, showed that tumors shrank in more than 50 percent of ASPS patients who were treated with cediranib. These findings […]
Minimally Invasive Procedures for Tumor Ablation
For Alveolar Soft Part Sarcoms patients the use of aggressive surgery, appropriate diagnostic imaging, and long-term surveillance for metastases are critical to achieve long-term survival (Kayton et al 2006). When surgery is not possible, then local treatment like tumor ablation may be considered. In the past we discussed the benefits of Stereotactic Radiosurgery (SRS). There are different […]
Laser Assisted Resection of Multiple Lung Metastases
Lung metastases affect a significant part of the ASPS patients at some point of their life, they can be very multiple and wide spread. It is very important to detect them early for an optimal management so all ASPS patients have to be monitored for the possible lung metastases development. For ASPS patients the use […]
Stereotactic Radiosurgery (SRS)
Stereotactic Radiosurgery (SRS) is a medical procedure, which is non-invasive surgery to destroy tumors. High dose of ionizing radiation is precisely delivered into a specific area of an organ to kill tumor cells. The beam of radiation is the surgical knife in radiosurgery. The most common forms of ionizing radiation are: proton beams, X-rays and […]